At BELLUS, we are focused on advancing novel therapeutics for conditions with high unmet medical need. Read More

At BELLUS, we are focused on advancing novel therapeutics for conditions with high unmet medical need. Read More

Blog

March 29, 2018 What a Difference Another Year Makes
(From the 2017 Annual Report)   Dear Shareholders, We are a little more than one year into our new business plan focused on BLU-5937 for chronic cough. I would like to tell you about the feedback we’ve received to date and how 2018 is shaping into a milestone year as we enter our first in-human studies. Positive Feedback When we first in-licensed BLU-5937 in February 2017, we vetted the...
Read More
February 9, 2018 BELLUS Health in a Volatile Market
Watching the markets fluctuate over the last few days, I am very grateful that we completed a $20M financing in December that: increased our cash runway to two+ years and through multiple important business milestones; included a wide spectrum of investors which diversifies our shareholder base involved significant participation from validating investors, including insiders and sophisticated...
Read More

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.